135 related articles for article (PubMed ID: 30803758)
1. Molecular mechanism of crolibulin in complex with tubulin provides a rationale for drug design.
Zhang Z; Wang C; Ma L; Jiang X; Wu C; Wang Y; Jiang Y; Zheng W; Yang Y; Ma Y; Yang J
Biochem Biophys Res Commun; 2019 Apr; 511(2):381-386. PubMed ID: 30803758
[TBL] [Abstract][Full Text] [Related]
2. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
[TBL] [Abstract][Full Text] [Related]
3. Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design.
Niu L; Wang Y; Wang C; Wang Y; Jiang X; Ma L; Wu C; Yu Y; Chen Q
Biochem Biophys Res Commun; 2017 Nov; 493(1):718-722. PubMed ID: 28864414
[TBL] [Abstract][Full Text] [Related]
4. Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent.
Yang H; Zhang D; Yuan Z; Qiao H; Xia Z; Cao F; Lu Y; Jiang F
Eur J Med Chem; 2024 Mar; 267():116205. PubMed ID: 38350361
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
Li Y; Yang J; Niu L; Hu D; Li H; Chen L; Yu Y; Chen Q
FEBS Lett; 2020 Jan; 594(1):199-204. PubMed ID: 31369682
[TBL] [Abstract][Full Text] [Related]
6. A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin.
Xian J; Bu F; Wang Y; Long F; Zhang Z; Wu C; Tao Y; Wang T; Wang G
Molecules; 2021 Feb; 26(4):. PubMed ID: 33579052
[TBL] [Abstract][Full Text] [Related]
7. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
8. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
[TBL] [Abstract][Full Text] [Related]
9. Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics.
Stec-Martyna E; Ponassi M; Miele M; Parodi S; Felli L; Rosano C
Curr Cancer Drug Targets; 2012 Jul; 12(6):658-66. PubMed ID: 22385515
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.
Kemnitzer W; Drewe J; Jiang S; Zhang H; Wang Y; Zhao J; Jia S; Herich J; Labreque D; Storer R; Meerovitch K; Bouffard D; Rej R; Denis R; Blais C; Lamothe S; Attardo G; Gourdeau H; Tseng B; Kasibhatla S; Cai SX
J Med Chem; 2004 Dec; 47(25):6299-310. PubMed ID: 15566300
[TBL] [Abstract][Full Text] [Related]
11. Prediction of new chromene-based inhibitors of tubulin using structure-based virtual screening and molecular dynamics simulation methods.
Aryapour H; Dehdab M; Sohraby F; Bargahi A
Comput Biol Chem; 2017 Dec; 71():89-97. PubMed ID: 28992456
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.
Kemnitzer W; Drewe J; Jiang S; Zhang H; Crogan-Grundy C; Labreque D; Bubenick M; Attardo G; Denis R; Lamothe S; Gourdeau H; Tseng B; Kasibhatla S; Cai SX
J Med Chem; 2008 Feb; 51(3):417-23. PubMed ID: 18197614
[TBL] [Abstract][Full Text] [Related]
13. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel class of tubulin inhibitors with promising anticancer activities.
Xi J; Zhu X; Feng Y; Huang N; Luo G; Mao Y; Han X; Tian W; Wang G; Han X; Luo R; Huang Z; An J
Mol Cancer Res; 2013 Aug; 11(8):856-64. PubMed ID: 23666368
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities.
Zhang H; Fang X; Meng Q; Mao Y; Xu Y; Fan T; An J; Huang Z
Eur J Med Chem; 2018 Sep; 157():380-396. PubMed ID: 30099258
[TBL] [Abstract][Full Text] [Related]
16. The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
Chengyong W; Jinghong X; Yanyan W; Qing-Jie X; Lingling M; Yuyan L; Hai C; Qian L; Quan Z; Bo S; Yuxi W
FEBS Lett; 2021 Jan; 595(2):195-205. PubMed ID: 33220079
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
18. New substituted 4H-chromenes as anticancer agents.
Patil SA; Wang J; Li XS; Chen J; Jones TS; Hosni-Ahmed A; Patil R; Seibel WL; Li W; Miller DD
Bioorg Med Chem Lett; 2012 Jul; 22(13):4458-61. PubMed ID: 22608389
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies.
Sharma S; Gupta MK; Saxena AK; Bedi PM
Anticancer Agents Med Chem; 2017; 17(2):230-240. PubMed ID: 27141882
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of anti-pancreatic cancer activity of plinabulin derivatives based on the co-crystal structure.
Fu Z; Hou Y; Ji C; Ma M; Tian Z; Deng M; Zhong L; Chu Y; Li W
Bioorg Med Chem; 2018 May; 26(8):2061-2072. PubMed ID: 29571653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
